Coxsackieviruses

Back

Background

Coxsackieviruses belong to the family Picornaviridae and the genus Enterovirus, which also includes poliovirus and echovirus. Enteroviruses are among the most common and important human pathogens. Coxsackieviruses share many characteristics with poliovirus. With control of poliovirus infections in much of the world, more attention has been focused on understanding the nonpolio enteroviruses such as coxsackievirus.

Coxsackieviruses are nonenveloped viruses with linear single-stranded RNA. Coxsackieviruses are divided into group A and group B viruses based on early observations of their pathogenicity in mice. Group A coxsackieviruses were noted to cause a flaccid paralysis, which was caused by generalized myositis, while group B coxsackieviruses were noted to cause a spastic paralysis due to focal muscle injury and degeneration of neuronal tissue. At least 23 serotypes (1-22, 24) of group A and 6 serotypes (1-6) of group B are recognized.

In general, group A coxsackieviruses tend to infect the skin and mucous membranes, causing herpangina, acute hemorrhagic conjunctivitis (AHC), and hand-foot-and-mouth (HFM) disease. Group B coxsackieviruses tend to infect the heart, pleura, pancreas, and liver, causing pleurodynia, myocarditis, pericarditis, and hepatitis.[1] Both group A and group B coxsackieviruses can cause nonspecific febrile illnesses, rashes, upper respiratory tract disease, and aseptic meningitis.

Numerous group A coxsackieviruses are responsible for causing CNS disease similar to poliomyelitis.[2] Systemic neonatal disease is often associated with group B coxsackieviruses.[2]

The development of insulin-dependent diabetes (IDDM) has recently been associated with recent enteroviral infection, particularly coxsackievirus B infection. This relationship is currently being studied further.

Pathophysiology

Coxsackieviruses are transmitted primarily via the fecal-oral route and respiratory aerosols, although transmission via fomites is possible. The viruses initially replicate in the upper respiratory tract and the distal small bowel. They have been found in the respiratory tract up to 3 weeks after initial infection and in feces up to 8 weeks after initial infection. The viruses have been found to replicate in the submucosal lymph tissue and disseminate to the reticuloendothelial system. Further dissemination to target organs occurs following a secondary viremia. Immunity is thought to be chiefly humoral.[2]

Epidemiology

Frequency

United States

Approximately 10 million symptomatic enteroviral infections are estimated to occur annually in the United States. From 2002-2004, an estimated 16.4-24.3% of these illnesses were attributed to coxsackievirus serotypes. For 2 of the 3 years, coxsackievirus B1 was the predominant serotype. Enteroviruses are responsible for approximately 30,000-50,000 hospitalizations per year.[3] The Centers for Disease Control and Prevention (CDC) found that coxsackievirus infections accounted for approximately 25% of all neonatal enterovirus infections (26,737) from 1983 to 2003.[4] Those due to coxsackievirus B4 were associated with a higher mortality rate than any other serotype.

International

Coxsackievirus infections have worldwide distribution. They can be isolated year-round in tropical climates, with a decreasing incidence of disease and seasonality in areas of higher latitude.

Mortality/Morbidity

Mortality due to coxsackievirus infection is uncommon. Neonates and immunocompromised individuals are at most risk for complications secondary to all enteroviral infections.

Sex

During the first decade, enteroviral infections are more common in males, with a male-to-female ratio of 2:1. The reason for this increased incidence is not well known.

Age

Coxsackievirus infection occurs in all age groups but is more common in young children and infants. Children are at higher risk of infection during the first year of life. The rate of illness decreases greatly following the first decade of life.

History

More than 90% of coxsackieviruses infections are asymptomatic or cause nonspecific febrile illnesses. In neonates, they are the most common cause of febrile illnesses during the summer and fall months. Thirteen percent of newborns with fever in the first month of life were noted to have an enteroviral infection. In addition to nonspecific illnesses, various well-described illnesses have been associated with coxsackievirus infections.

Aseptic meningitis

Patients with aseptic meningitis may have rapid or gradual onset of fever and chills, nausea and vomiting, malaise, headaches, neck pain, light sensitivity, and upper respiratory symptoms. Infants younger than 3 months have been noted to have the highest incidence of clinically recognized aseptic meningitis, partly because lumbar punctures are often performed for the evaluation of fever in this age group. These infants often present with only a febrile illness characterized by irritability and anorexia. Meningismus occurs in only approximately 50% of infants with enteroviral meningitis.

Coxsackievirus B infection is more likely than coxsackievirus A to be associated with meningitis.

Seizures, lethargy, and movement disorders occur early in the course of disease and have been reported in 5-10% of patients with enteroviral meningitis. No long-term neurologic deficits appear to exist in infants with aseptic meningitis. Adults may experience a more prolonged period of fever and headache compared with infants and children.

Encephalitis

Encephalitis is an unusual manifestation of CNS infection, although it is sometimes observed in association with aseptic meningitis. Enteroviruses accounts for approximately 5% of all cases of encephalitis. Coxsackievirus types A9, B2, and B5 have been linked with encephalitis. In rare cases, it mimics encephalitis secondary to herpes simplex virus.

Neurologic diseases

Rarely, coxsackieviruses have been implicated in additional neurologic diseases such as sporadic cases of flaccid motor paralysis that closely mimic poliovirus infection. Additionally, cases of Guillain-Barré syndrome have been described with coxsackievirus serotypes A2, A5, and A9.

Myopericarditis

Myopericarditis can occur at any age although has a predilection for adolescents and young adults. Enteroviruses account for half of all cases of acute viral myopericarditis.

Manifestations of myopericarditis range from an asymptomatic presentation to heart failure and death. Between the two extremes, most patients report dyspnea, chest pain, fever, and malaise.

Symptoms may be preceded by an upper respiratory infection within the preceding 7-14 days.

Presenting signs include pericardial friction rub, gallop rhythm, and cardiomegaly and/or pericardial effusion on chest radiography.

ECG abnormalities may range from ST-segment elevations to heart block. Echocardiography may show diminished ejection fractions and left ventricular wall abnormalities. Myocardial enzyme levels in the serum are frequently elevated.

The male-to-female ratio is 2:1. The mortality rate is low, and the prognosis in children is believed to be better than that in adults. Complications include pericardial effusion, arrhythmia, heart block, valvular dysfunction, and dilated cardiomyopathy.

Diabetes

Although principally correlative, data suggest that type-1 insulin-dependent diabetes may result from group B coxsackievirus infections. Epidemiologic data note that clustering of newly onset diabetes mellitus occurs 1-3 months following infection with the virus. Similarly, animal models noted infection of pancreatic islet cells.

Exanthems

Two of the more distinctive exanthems caused by coxsackievirus hand-food-and-mouth disease (HFMD) and herpangina.

HFMD often affects children and spreads easily to other family members. Patients present with a sore throat and mouth. Vesicles that coalesce, form bullae, and then ulcerate form on the buccal mucosa and tongue. Seventy-five percent of patients have peripheral cutaneous lesions at approximately the same time. Biopsy reveals intracytoplasmic viral particles. The most common virus isolated is coxsackievirus A16. Numerous cases of a more severe HFMD caused by coxsackievirus A6 were reported between 2004 and 2011 in several Asian and European countries.[5] Additionally, between 2011 and 2012 in the United States, several cases of severe HFMD were reported, with 74% of those cases testing PCR positive for coxsackievirus A6; about 25% of reported cases were in adults.[5]

Herpangina is a vesicular enanthem of the posterior oropharynx with fever, sore throat, occasional throat exudate, odynophagia, and dysphagia, which is observed more often in young children than in adolescents and adults. Prompt recovery is typical, with almost all patients recovering completely. Group A coxsackieviruses are the most common viruses isolated from herpangina patients.

Epidemic pleurodynia

This is a muscular disease, and viral invasion of muscles, causing inflammation, is suspected; however, direct histologic evidence is lacking. Epidemic pleurodynia is usually associated with outbreaks of group B coxsackievirus infection.

Patients present with fever and sharp, paroxysmal, spasmodic pain in the chest and upper abdomen.

All patients recover completely within 1 week.

Acute hemorrhagic conjunctivitis

Pain and edema of the eyelids and subconjunctival hemorrhage are present.

Patients may also report photophobia, foreign body sensation, fever, malaise, and headache. These symptoms usually resolve spontaneously within one week.

Rare complications include keratitis and motor paralysis.

This condition is highly contagious and has resulted in epidemics and pandemics.

Physical

Aseptic meningitis

On examination, patients may have signs of nuchal rigidity and other evidence of meningeal irritation, photophobia, pharyngitis, and rash.

Encephalitis

In contrast to patients with aseptic meningitis, whose brain function is normal, patients with encephalitis may present with cerebral dysfunction that manifests as altered mental status, personality changes, and neurologic deficits (eg, motor, sensory, speech impairment). An EEG may be helpful in localizing and characterizing the seizure focus.

Myopericarditis

The presentation in patients with myopericarditis ranges from asymptomatic to critical illness secondary to severe heart failure. Most patients report fever, malaise, upper respiratory tract symptoms, dyspnea, and chest pain. Chest pain increases when the patient is lying down and improves when the patient sits up and leans forward.

On examination, the point of maximal pulse (PMI) may be displaced, pericardial friction rub may be heard, and signs of heart failure (eg, S3 gallop, pulmonary edema) may be present.

HFMD

Physical examination findings include vesicular lesions that may appear on the tongue or buccal mucosa, as well as the hands and feet, including the palms and soles. Uncommonly, the buttocks and genitalia are involved. The vesicles are tender and may ulcerate. However, the vesicles are usually not pruritic, which helps to distinguish them from chickenpox lesions.

Epidemic pleurodynia

On physical examination, edema of the involved muscles and tenderness to palpation may occur.

Acute hemorrhagic conjunctivitis (AHC)

Physical examination findings include subconjunctival hemorrhage. Eye pain, edema of the eyelids, photophobia, and a serous discharge may be present. Slit lamp examination may reveal keratitis.

Causes

Aseptic meningitis

Coxsackievirus B (serotypes 2-5) and echoviruses account for more than 90% of viral causes of aseptic meningitis.

Exanthems

Coxsackieviruses cause many different types of rashes. Whether the viruses directly cause the rashes or immunologic mechanisms are responsible for the rashes is not known. An exception is HFM, in which viruses are isolated directly from the lesions. HFM is predominantly caused by coxsackievirus A16. In most other instances, rashes can be attributed to coxsackieviruses only if findings on concurrent polymerase chain reaction (PCR) or serology are positive.

AHC

Coxsackievirus serotype A24 generally causes AHC. Transmission usually occurs via contact of contaminated fingers or fomites with the eyes. To prevent further transmission, strict handwashing should be encouraged and sharing of towels should be avoided.

Laboratory Studies

Definitive diagnosis can be made based on isolation of the virus in cell culture. Cytopathic effect can usually be seen within 2-6 days. Samples are normally taken from the stool or rectal swabs but may be isolated from the oropharynx early in the disease course. False-positive culture results are possible, as excretion can occur for up to 8 weeks after initial infection. Serology can be difficult to interpret. Traditionally, enteroviral infections have been noted after a rise in neutralizing antibodies titer (at least a 4-fold rise in titer between acute and convalescent phase). PCR is also available, with a sensitivity of 66-90%.

Aseptic meningitis

The workup needs to rule out bacterial meningitis, and appropriate antibiotics should be administered until the workup is complete. Diagnosis requires cerebrospinal fluid (CSF) evaluation, which tends to show a lymphocytic predominance, normal-to-decreased glucose levels, and normal-to-slightly elevated protein levels. The virus can be isolated via cell culture (sensitivity, 30-35%) or PCR (sensitivity, 66-90%). A recent study in infants reported that routine CSF PCR for enteroviruses resulted in shorter hospital stays (by 1.54 days) and a decreased duration of antibiotic use (by 33%).[6]

Encephalitis

Diagnostic workup requires CSF evaluation, which yields findings similar to those of aseptic meningitis.

Myopericarditis

Diagnosis is generally circumstantial, with evidence of infection from the oropharynx, feces, or on serology.

Acute hemorrhagic conjunctivitis (AHC)

Diagnosis requires conjunctival swabs or scrapings, which are 90% successful. A rising antibody titer can be demonstrated.

Imaging Studies

Head CT scanning without contrast may be obtained upon initial presentation of meningitis and/or encephalitis to rule out hemorrhage, increased intracranial pressure, or mass lesions.

Echocardiography can be used to evaluate overall cardiac function and valvular disease in patients with myopericarditis and heart failure.

Other Tests

Obtain a throat culture to rule out streptococcal pharyngitis and/or tonsillitis.

HIV testing is always appropriate in patients who present with nonspecific febrile illness or rashes.

An EEG can be used to detect the presence of and localize seizure activity.

ECG changes in myopericarditis include ST-segment elevations or nonspecific ST segment, T-wave abnormalities, arrhythmia, and heart block.

Procedures

Lumbar puncture is crucial in the evaluation of meningitis and/or encephalitis.

Skin biopsy may be helpful in the evaluation of nonspecific exanthems.

Obtain a Tzank smear to rule out herpes virus infection.

Histologic Findings

Intracytoplasmic viral particles may be observed, especially with skin lesions and/or rashes of HFM.

Medical Care

Medical care is generally supportive and can be offered on an outpatient basis. More severe symptoms may require inpatient admission for further workup and intervention.

Aseptic meningitis

Treatment is mainly supportive.

Pleconaril, an enteroviral capsid-stabilizing drug, appeared to reduce symptoms in a randomized double-blind study (N = 33),[7] but has not been licensed by the Food and Drug Administration (FDA).

Not all patients require hospitalization, but consider admission for patients with changes in mental status or neurologic deficits.

Myopericarditis

IVIG has been of anecdotal benefit, but no randomized trials have been conducted. A large prospective trial of prednisone with cyclosporine or azathioprine showed no difference compared to supportive treatment alone.[8] Recent experiments have shown that carvedilol, a nonselective beta-blocker, attenuates myocardial lesions and decreases myocardial virus replication in a murine model. However, this intervention has not been evaluated in humans.[9]

Epidemic pleurodynia

Analgesics, narcotics, and heating pads are the mainstays of therapy. All patients recover completely within 1 week.

Acute hemorrhagic conjunctivitis (AHC)

Treatment is symptomatic, and no antimicrobial agent is necessary in the absence of bacterial superinfection.

Immunodeficiency

Both IVIG and pleconaril have been used in immunocompromised patients with enteroviral infections (neonates and B-cell immunodeficient) with varying success.

In vitro studies have suggested that arbidol may have potential as a future antiviral agent with activity against coxsackievirus, but no trials in humans have yet been performed.[10]

Surgical Care

No surgical intervention is necessary unless patients develop complications such as meningitis and/or encephalitis with increased intracranial pressure, which requires ventriculostomy, or heart failure, which requires valve repair or cardiac transplant.

Consultations

Consultations play an important role in patients with complex presentations.

A neurologist may help to evaluate patients who present with abnormal neurologic symptoms or to manage rare complications associated with meningitis.

A neurosurgeon may be needed to assist with obtaining brain biopsies or placing a ventriculostomy tube because of increased intracranial pressure.

A cardiologist helps with diagnosis and management of arrhythmia, heart failure, and heart block associated with myocarditis.

Diet

Diet is as tolerated.

Activity

Bedrest is indicated for some patients.

Medication Summary

No FDA-approved therapy exists for the treatment of enteroviral infections. IVIG and pleconaril have been used in severe illness. Supportive use of analgesics and antipyretics are usually necessary.

Further Outpatient Care

No outpatient care, other than usual follow-up care, is required for patients with mild symptoms.

Further Inpatient Care

Severe aseptic meningitis and/or encephalitis, seizures, myopericarditis, and heart failure require admission for workup and treatment. Antibiotics may be used until bacterial meningitis is ruled out. Supportive inpatient or intensive care may be necessary for severe cases.

Inpatient & Outpatient Medications

Inpatient medications indicated are based on the patient's presentation at admission (eg, phenytoin for seizure prophylaxis and/or suppression in patients with aseptic meningitis/encephalitis, digoxin in patients with heart failure).

Antipyretics (eg, acetaminophen) for fever and NSAIDs for pain should be adequate in patients with mild symptoms who do not require hospital admission.

Transfer

Transfer to a tertiary facility may be necessary for specialized consultations or surgeries.

Deterrence/Prevention

Minimize respiratory contact with the infected patient if possible.

To prevent further transmission, strict handwashing should be encouraged and sharing of towels should be avoided.

Complications

See History and Physical, which discuss the many presentations of coxsackievirus infections.

Complications of aseptic meningitis include lethargy, seizures, coma, and movement disorders (5-10%).

Complications of myopericarditis include pericardial effusion, arrhythmia, heart block, valvular dysfunction, and dilated cardiomyopathy.

Rare complications of acute hemorrhagic conjunctivitis (AHC) include keratitis and motor paralysis.

Prognosis

In general, the prognosis is very good, with 90% of patients having no symptoms or experiencing mild, self-limited, nonspecific febrile illnesses or rashes.

Patient Education

Patients should be aware of the need for good hygiene practices to avoid transmission.

Patients need to be reassured that they have a self-limited viral illness that does not require any antibiotics for treatment.

What are coxsackieviruses?What is the difference between group A and group B coxsackieviruses?What is the pathophysiology of coxsackievirus infection?What is the prevalence of coxsackievirus infection in the US?What is the global prevalence of coxsackievirus infections?What is the mortality risk for coxsackievirus infection?How does the prevalence of coxsackievirus infection vary by sex?How does the prevalence of coxsackievirus infection vary by age?How prevalent is coxsackievirus encephalitis?What are the signs and symptoms of coxsackievirus myopericarditis?Which history findings are characteristic of coxsackievirus infections?What are the signs and symptoms of aseptic meningitis caused by coxsackieviruses?Which neurologic diseases are caused by coxsackieviruses?What is the role of coxsackievirus infection in the etiology of diabetes?What are the signs and symptoms of exanthems caused by coxsackievirus infection?What are the signs and symptoms of pleurodynia caused by coxsackievirus infection?What are the signs and symptoms of acute coxsackievirus hemorrhagic conjunctivitis?Which physical findings suggest coxsackievirus aseptic meningitis?Which physical findings suggest coxsackievirus encephalitis?Which physical findings suggest coxsackievirus myopericarditis?Which physical findings suggest hand, foot, and mouth disease (HFMD) caused by coxsackievirus infection?Which physical findings suggest coxsackievirus pleurodynia?Which physical findings suggest coxsackievirus acute hemorrhagic conjunctivitis (AHC)?How frequently does coxsackievirus infection cause aseptic meningitis?What is the etiologic role of coxsackieviruses in exanthems?What is the etiologic role of coxsackieviruses in acute hemorrhagic conjunctivitis (AHC)?Which conditions should be included in the differential diagnosis of coxsackievirus aseptic meningitis?Which conditions should be included in the differential diagnosis of coxsackievirus encephalitis?Which conditions should be included in the differential diagnosis of coxsackievirus myopericarditis?Which conditions should be included in the differential diagnosis of coxsackievirus hand, foot, and mouth disease (HFMD)?Which conditions should be included in the differential diagnosis of coxsackievirus herpangina?Which conditions should be included in the differential diagnosis of coxsackievirus epidemic pleurodynia?Which conditions should be included in the differential diagnosis of coxsackievirus acute hemorrhagic conjunctivitis?What are the differential diagnoses for Coxsackieviruses?What is the role of lab studies in the diagnosis of coxsackievirus infection?What is the role of lab studies in the workup coxsackievirus aseptic meningitis?What is the role of lab studies in the workup of coxsackievirus encephalitis?What is the role of lab studies in the workup of coxsackievirus myopericarditis?What is the role of lab studies in the workup of coxsackievirus acute hemorrhagic conjunctivitis (AHC)?What is the role of imaging studies in the evaluation of coxsackievirus infection?Which tests may be useful in the evaluation of coxsackievirus infection?Which procedures may be useful in the evaluation of coxsackievirus infection?Which histologic findings are characteristic of coxsackievirus infections?What is the approach to treatment of coxsackievirus infection?What is included in medical care for coxsackievirus aseptic meningitis?What is included in medical care for coxsackievirus myopericarditis?What is included in medical care for coxsackievirus epidemic pleurodynia?What is included in medical care for coxsackievirus acute hemorrhagic conjunctivitis (AHC)?What is included in medical care for immunodeficiency in patients with coxsackievirus infections?What is the role of surgery in the treatment of coxsackievirus infection?Which specialist consultations are needed for the treatment of coxsackievirus infection?Which dietary modifications are needed for patients with coxsackievirus infection?Which activity modifications are needed for patients with coxsackievirus infection?What is the role of medications in the treatment of coxsackievirus infection?What is included in the follow-up care for patients with coxsackievirus infection?When is inpatient care indicated for patients with coxsackievirus infection?Which medications are used in the treatment of coxsackievirus infections?When is transfer needed for patients with coxsackievirus infection?How is coxsackievirus infection prevented?What are the complications of coxsackievirus infection?What is the prognosis of coxsackievirus infection?What should be included in patient education about coxsackieviruses?

Author

Martha L Muller, MD, MPH, Professor of Pediatrics, Division of Infectious Diseases, University of New Mexico School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John W King, MD, Professor of Medicine, Chief, Section of Infectious Diseases, Director, Viral Therapeutics Clinics for Hepatitis, Louisiana State University Health Sciences Center; Consultant in Infectious Diseases, Overton Brooks Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.

Additional Contributors

Maria D Mileno, MD, Associate Professor of Medicine, Division of Infectious Diseases, The Warren Alpert Medical School of Brown University

Disclosure: Nothing to disclose.

Acknowledgements

Mashiul H Chowdhury, MD Assistant Professor, Department of Medicine, Division of Infectious Disease, Program Director, Infectious Disease Fellowship, Director, TravelHealth Center, Drexel University College of Medicine

Disclosure: Nothing to disclose.

Nhat M Doan, MD Fellow, Department of Internal Medicine, Division of Infectious Diseases, Washington Hospital Center

Disclosure: Nothing to disclose.

Parul Kaushik, MD, MPH Fellow, Department of Medicine, Division of Infectious Disease, Drexel University College of Medicine

Disclosure: Nothing to disclose.

Michael Rajnik, MD Associate Professor, Department of Pediatrics, Program Director, Pediatric Infectious Disease Fellowship Program, Uniformed Services University of the Health Sciences

Michael Rajnik is a member of the following medical societies: American Academy of Pediatrics, Armed Forces Infectious Disease Society, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society.

Disclosure: Nothing to disclose.

References

  1. Lim BK, Ju ES, Lao DH, Yun SH, Lee YJ, Kim DK, et al. Development of a enterovirus diagnostic assay system for diagnosis of viral myocarditis in humans. Microbiol Immunol. 2013 Apr. 57(4):281-7. [View Abstract]
  2. Muehlenbachs A, Bhatnagar J, Zaki SR. Tissue tropism, pathology and pathogenesis of enterovirus infection. J Pathol. 2014 Sep 11. [View Abstract]
  3. Kadambari S, Bukasa A, Okike IO, Pebody R, Brown D, Gallimore C. Enterovirus infections in England and Wales, 2000-2011: the impact of increased molecular diagnostics. Clin Microbiol Infect. 2014 Jul 4. [View Abstract]
  4. Khetsuriani N, Lamonte A, Oberste MS, et al. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983-2003. Pediatr Infect Dis J. 2006 Oct. 25(10):889-93. [View Abstract]
  5. Stewart CL, Chu EY, Introcaso CE, Schaffer A, James WD. Coxsackievirus A6-induced hand-foot-mouth disease. JAMA Dermatol. 2013 Dec. 149(12):1419-21. [View Abstract]
  6. King RL, Lorch SA, Cohen DM, et al. Routine cerebrospinal fluid enterovirus polymerase chain reaction testing reduces hospitalization and antibiotic use for infants 90 days of age or younger. Pediatrics. 2007 Sep. 120(3):489-96. [View Abstract]
  7. Schiff GM, Sherwood JR. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis. 2000 Jan. 181(1):20-6. [View Abstract]
  8. Brunetti L, DeSantis ER. Treatment of viral myocarditis caused by coxsackievirus B. Am J Health Syst Pharm. 2008 Jan 15. 65(2):132-7. [View Abstract]
  9. Yue-Chun L, LiSha G, Jiang-Hua R, Peng-Lin Y, Jia-Feng L, Ji-Fei T, et al. Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovas Pharmacol. Jan/2008. 51:92-98. [View Abstract]
  10. Shi L, Xiong H, He J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007. 152(8):1447-55. [View Abstract]
  11. Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore. 2009 Feb. 38(2):106-12. [View Abstract]
  12. Bergman I, Painter MJ, Wald ER, et al. Outcome in children with enteroviral meningitis during the first year of life. J Pediatr. 1987 May. 110(5):705-9. [View Abstract]
  13. Berlin LE, Rorabaugh ML, Heldrich F, et al. Aseptic meningitis in infants < 2 years of age: diagnosis and etiology. J Infect Dis. 1993 Oct. 168(4):888-92. [View Abstract]
  14. Cheung CT, Deisher TA, Luo H, et al. Neutralizing anti-4-1BBL treatment improves cardiac function in viral myocarditis. Lab Invest. 2007 Jul. 87(7):651-61. [View Abstract]
  15. Dagan R, Jenista JA, Menegus MA. Association of clinical presentation, laboratory findings, and virus serotypes with the presence of meningitis in hospitalized infants with enterovirus infection. J Pediatr. 1988 Dec. 113(6):975-8. [View Abstract]
  16. Dagan R, Menegus MA. A combination of four cell types for rapid detection of enteroviruses in clinical specimens. J Med Virol. 1986 Jul. 19(3):219-28. [View Abstract]
  17. Dulbecco R, Ginsberg H. Virology. 2nd ed. 1988. 207-209.
  18. Enterovirus surveillance--United States, 2002-2004. MMWR Morb Mortal Wkly Rep. 2006 Feb 17. 55(6):153-6. [View Abstract]
  19. Jaïdane H, Hober D. Role of coxsackievirus B4 in the pathogenesis of type 1 diabetes. Diabetes Metab. 2008 Dec. 34(6 Pt 1):537-48. [View Abstract]
  20. Jenista JA, Powell KR, Menegus MA. Epidemiology of neonatal enterovirus infection. J Pediatr. 1984 May. 104(5):685-90. [View Abstract]
  21. Levinson W, Jawetz E. Medical Microbiology & Immunology: Examination & Board Review. 6th ed. New York, NY: McGraw Hill Text; 2000. 238-239.
  22. Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014 Feb. 10(2):360-7. [View Abstract]
  23. Modlin JF. Coxsackieviruses, Echoviruses, Newer Enteroviruses, and Parechoviruses. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Churchill-Livingstone; 2009. 2353-2365.
  24. Moore M. Centers for Disease Control. Enteroviral disease in the United States, 1970-1979. J Infect Dis. 1982 Jul. 146(1):103-8. [View Abstract]
  25. Morens DM, Pallansch MA. Epidemiology. Human Enterovirus Infections. 1995. 1:
  26. Morgan NG, Richardson SJ. Enteroviruses as causative agents in type 1 diabetes: loose ends or lost cause?. Trends Endocrinol Metab. 2014 Aug 28. [View Abstract]
  27. Pallansch MA, Anderson LJ. Coxsackievirus, echovirus, and other enteroviruses. Gorbach SL, ed. Infectious Diseases. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1998. 2164-2170.
  28. Piqueur MA, Verstrepen WA, Bruynseels P, Mertens AH. Improvement of a real-time RT-PCR assay for the detection of enterovirus RNA. Virol J. 2009 Jul 7. 6:95. [View Abstract]
  29. Rantala H, Uhari M. Occurrence of childhood encephalitis: a population-based study. Pediatr Infect Dis J. 1989 Jul. 8(7):426-30. [View Abstract]
  30. Richer MJ, Horwitz MS. Coxsackievirus infection as an environmental factor in the etiology of type 1 diabetes. Autoimmun Rev. 2009 Jun. 8(7):611-5. [View Abstract]
  31. Rorabaugh ML, Berlin LE, Heldrich F, et al. Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications. Pediatrics. 1993 Aug. 92(2):206-11. [View Abstract]
  32. Rotbart HA. Pleconaril therapy of potentially life-threatening enterovirus infections. 36th Annual Meeting of the Infectious Disease Society of America. 1998.
  33. Rotbart HA. Pleconaril treatment of enterovirus and rhinovirus infections. Infect Med. 2000. 17:488.
  34. Rotbart HA. Treatment of picornavirus infections. Antiviral Res. 2002 Feb. 53(2):83-98. [View Abstract]
  35. Rotbart HA, Ahmed A, Hickey S, et al. Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types. Pediatr Infect Dis J. 1997 Apr. 16(4):409-11. [View Abstract]
  36. Rotbart HA, McCracken GH Jr, Whitley RJ, et al. Clinical significance of enteroviruses in serious summer febrile illnesses of children. Pediatr Infect Dis J. 1999 Oct. 18(10):869-74. [View Abstract]
  37. Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 2001 Jan 15. 32(2):228-35. [View Abstract]
  38. Sauter P, Hober D. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect. 2009 Apr. 11(4):443-51. [View Abstract]
  39. Sawyer MH, Holland D, Aintablian N, et al. Diagnosis of enteroviral central nervous system infection by polymerase chain reaction during a large community outbreak. Pediatr Infect Dis J. 1994 Mar. 13(3):177-82. [View Abstract]
  40. Tebruegge M, Curtis N. Enterovirus infections in neonates. Semin Fetal Neonatal Med. 2009 Aug. 14(4):222-7. [View Abstract]
  41. Voroshilova MK, Chumakov MP. Poliomyelitis-like properties of AB-IV Coxsackie A7 group of viruses. Prog Med Virol. 1959. 2:106.
  42. Weller TH, Enders JF, Buckingham M, et al. The etiology of epidemic pleurodynia: a study of two viruses isolated from a typical outbreak. J Immunol. 1950 Sep. 65(3):337-46. [View Abstract]
  43. Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ. 3 February 2011. 342:1-9. [View Abstract]